By: Christopher A. Parrella, Esq., CPC, CHC, CPCO Parrella Health Law, Boston, Ma. A Health Care Provider Defense and Compliance Firm

The Future of Telemedicine Prescriptions: What the Third Temporary Extension Means for the Prescribing of Controlled Meds

A Brief History of Telemedicine Flexibilities

The COVID-19 pandemic catalyzed a shift in healthcare delivery, allowing telemedicine to flourish. Under the Ryan Haight Act, practitioners traditionally had to conduct in-person evaluations before prescribing controlled substances. However, exceptions were granted during the pandemic, enabling audio-video telemedicine visits to substitute for in-person evaluations.

Since March 2020, these temporary flexibilities have allowed practitioners to prescribe Schedule II-V controlled substances, including opioid use disorder treatments like buprenorphine, through telemedicine. This approach expanded access to care for millions, particularly in underserved and rural areas.

Key Highlights of the Third Temporary Rule

The COVID-19 pandemic catalyzed a shift in healthcare delivery, allowing telemedicine to flourish. Under the Ryan Haight Act, practitioners traditionally had to conduct in-person evaluations before prescribing controlled substances. However, exceptions were granted during the pandemic, enabling audio-video telemedicine visits to substitute for in-person evaluations.

Since March 2020, these temporary flexibilities have allowed practitioners to prescribe Schedule II-V controlled substances, including opioid use disorder treatments like buprenorphine, through telemedicine. This approach expanded access to care for millions, particularly in underserved and rural areas.

Key Highlights of the Third Temporary Rule

1. Extension of Telemedicine Flexibilities: The new rule maintains the COVID-era telemedicine practices, allowing practitioners to prescribe controlled medications via telehealth without an in-person evaluation until the end of 2025.
2. Mitigating Public Health Challenges: The DEA and HHS emphasized that this extension is crucial to addressing public health crises, such as the ongoing opioid epidemic, by ensuring continued access to necessary treatments.
3. Future Regulatory Pathways:
   • Stakeholder feedback from listening sessions, tribal consultations, and public comments will shape future permanent rules.
   • The extension provides a bridge while final regulations are crafted to balance patient care and diversion prevention.
4. Practitioner Compliance: Practitioners must adhere to existing regulations, including issuing prescriptions for legitimate medical purposes and following all applicable state and federal laws.

What This Means for Patients and Providers

• For Patients: This extension prevents disruptions in care, ensuring that individuals relying on telemedicine for controlled substance prescriptions maintain access.
• For Providers: Healthcare professionals gain additional time to prepare for potential permanent regulations, avoiding administrative and logistical challenges associated with transitioning back to pre-pandemic standards.

Challenges and Opportunities

While the extension offers relief, the path to permanent telemedicine policies remains complex. Key considerations include:

• Preventing Diversion: Ensuring controlled substances are prescribed responsibly to mitigate risks of misuse.
• Balancing Access and Oversight: Striking the right balance between patient access and regulatory compliance is critical.
• Future Stakeholder Collaboration: Continued input from clinicians, patients, and industry stakeholders will be essential to crafting effective and equitable policies.

Call to Action: Stay Ahead of the Curve

This extension is a temporary measure, but the future of telemedicine prescribing is rapidly unfolding. Parrella Health Law is here to help healthcare providers navigate these regulatory shifts and ensure compliance while delivering exceptional patient care.

If you have questions about how the Third Temporary Rule impacts your practice or need guidance on telemedicine and controlled substance prescribing compliance, contact Parrella Health Law at 857-328-0382 or email Chris directly at cparrella@parrellahealthlaw.com. Let us help you stay ahead in this dynamic regulatory environment.